Head and Neck Cancer Preclinical Research Services

Efficacy Testing Services

• Customized In Vitro Assays: Develop tailored in vitro models using various HNC cell lines (e.g., SCC-25, FaDu) to precisely evaluate the therapeutic potential of your compounds through cell viability, migration, and invasion assays.
• In Vivo Efficacy Studies: Utilize state-of-the-art xenograft and genetically engineered mouse models to demonstrate tumor response to therapies, including long-term survival and treatment combination studies to identify synergistic effects.
• Biomarker Analysis: Implement predictive biomarker assessments to correlate treatment responses, providing insights into patient stratification for clinical trials.

Safety Testing Services

• Comprehensive In Vitro Toxicity Profiling: Conduct detailed toxicity assessments using relevant normal cell lines and 3D organoid models to evaluate selective cytotoxicity and minimize risks in clinical settings.
• In Vivo Toxicology Evaluations: Assess maximum tolerated doses (MTD) and potential organ toxicities in rodent models, including specific evaluations for mucositis and systemic effects, ensuring your drug candidates are safe for human trials.

Pharmacokinetics (PK) Services

• Comprehensive PK Studies: Analyze absorption, distribution, metabolism, and excretion of new drug candidates to understand their pharmacological profiles.
• Tumor Penetration Studies: Measure drug levels in tumor tissues compared to plasma, offering crucial data on effective concentrations within the tumor microenvironment.
• Specialized Drug Administration Routes: Evaluate both oral and intravenous dosing regimens to identify optimal delivery methods for your therapies.

Pharmacodynamics (PD) Services

• Mechanistic Studies: Investigate the biological effects of your drugs, focusing on target engagement and modulation of signaling pathways through advanced techniques like Western blotting and flow cytometry.
• Imaging and Biomarker Assessment: Utilize sophisticated imaging modalities, including PET-CT and MRI, to track tumor responses and correlate these findings with biomarker changes for real-time analysis of treatment efficacy.
• PK/PD Modeling: Develop predictive models that link pharmacokinetic properties with pharmacodynamic effects, assisting in dose optimization and enhancing the translational relevance of your research.